Measurement of extended half-life recombinant factor IX products in clinical practice
Corresponding Author
Annette E. Bowyer
Department Of Coagulation, Royal Hallamshire Hospital, Sheffield, UK
Correspondence
Annette E. Bowyer, Sheffield Haemophilia and Thrombosis Centre, Royal Hallamshire Hospital, Sheffield, UK.
Email: [email protected]
Search for more papers by this authorM. Fiona Shepherd
Department Of Coagulation, Royal Hallamshire Hospital, Sheffield, UK
Search for more papers by this authorSteve Kitchen
Department Of Coagulation, Royal Hallamshire Hospital, Sheffield, UK
Search for more papers by this authorRhona M. Maclean
Sheffield Haemophilia and Thrombosis Centre, Royal Hallamshire Hospital, Sheffield, UK
Search for more papers by this authorMike Makris
Department Of Coagulation, Royal Hallamshire Hospital, Sheffield, UK
Cardiovascular Science, University of Sheffield, Sheffield, UK
Search for more papers by this authorCorresponding Author
Annette E. Bowyer
Department Of Coagulation, Royal Hallamshire Hospital, Sheffield, UK
Correspondence
Annette E. Bowyer, Sheffield Haemophilia and Thrombosis Centre, Royal Hallamshire Hospital, Sheffield, UK.
Email: [email protected]
Search for more papers by this authorM. Fiona Shepherd
Department Of Coagulation, Royal Hallamshire Hospital, Sheffield, UK
Search for more papers by this authorSteve Kitchen
Department Of Coagulation, Royal Hallamshire Hospital, Sheffield, UK
Search for more papers by this authorRhona M. Maclean
Sheffield Haemophilia and Thrombosis Centre, Royal Hallamshire Hospital, Sheffield, UK
Search for more papers by this authorMike Makris
Department Of Coagulation, Royal Hallamshire Hospital, Sheffield, UK
Cardiovascular Science, University of Sheffield, Sheffield, UK
Search for more papers by this author
REFERENCES
- 1Chowdary P, Kearney S, Regnault A, Hoxer CS, Yee DL. Improvement in health-related quality of life in patients with haemophilia B treated with nonacog beta pegol, a new extended half-life recombinant FIX product. Haemophilia. 2016; 22: e267–e274.
- 2Sommer JM, Buyue Y, Bardan S, et al. Comparative field study: impact of laboratory assay variability on the assessment of recombinant factor IX Fc fusion protein (rFIXFc) activity. Thromb Haemost. 2014; 112: 932-940.
- 3St Ledger K, Feussner A, Kalina U, Jacobs I, Viogt C, Bensen-Kennedy D. Performance of a recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) in the one-stage assay. Haemophilia. 2016; 22: 60.
- 4 Europe Co. Human Coagulation factor IX. Monograph 1644. Strasbourg: Ph. Eur. 8th Edition. 2014.
- 5 EMA, editor Workshop report: Characterisation of new clotting factor concentrates (FVIII, FIX) with respect to potency assays used for labelling and testing of post infusion samples. EMA; 2014; London.
- 6Bowyer AE, Hillarp A, Ezban M, Persson P, Kitchen S. Measuring factor IX activity of nonacog beta pegol with commercially available one-stage clotting and chromogenic assay kits: a two centre study. J Thromb Haemost. 2016; 14: 1428-1435.
- 7Geske FJ, Sadeghi-Khomami A. Recombinant factor IX Fc fusion protein (rFIXFc) clotting activity assessment in international haemophilia treatment centres. Chicago, IL: THSNA; 2016.
- 8Tiefenbacher S, Bohra R, Amirel J, et al. Qualification of a select one-stage activated partial thromboplastin time-based clotting assay and two chromogenic assays for the post-administration monitoring of nonacog beta pegol. J Thromb Haemost. 2017; 15: 1-12.
- 9Peyvandi F, Oldenburg J, Friedman KD. A critical appraisal of one-stage and chromogenic assays of factor VIII activity. J Thromb Haemost. 2016; 14: 248-261.
- 10Collins PW, Chalmers E, Chowdary P, et al. The use of enhanced half-life coagulation factor concentrates in routine clinical practice: guidance from UKHCDO. Haemophilia. 2016; 22: 487-498.
Citing Literature
